Literature DB >> 1499643

Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation.

O F Wagner1, H Vierhapper, S Gasic, P Nowotny, W Waldhäusl.   

Abstract

To determine the impact of i.v. endothelin-1 on systemic, pulmonary and splanchnic circulation, as well as the peptide's regional clearance, hepatic venous and right heart catheterization was performed in healthy volunteers. During the peptide's continuous i.v. administration (0.4 pmol x kg-1 x min-1, 60 min) its plasma concentration rose from 2.1 +/- 0.5 to 9.5 +/- 5.3 pmol/l (pulmonary artery), from 2.1 +/- 0.9 to 5.0 +/- 1.6 pmol/l (femoral artery), and from 1.5 +/- 0.6 to 2.9 +/- 1.2 pmol/l (hepatic vein). This was accompanied by an increase in mean systolic arterial pressure from 127 +/- 14 to 131 +/- 12 mmHg (P less than 0.05). Concomitantly, cardiac output and heart rate decreased from 7.0 +/- 1.1 to 5.8 +/- 1.0 l/min and from 63 +/- 6 to 56 +/- 5 beats/min, respectively, while total vascular resistance increased from 964 +/- 273 to 1204 +/- 338 dyn x cm x s-5 (P less than 0.01). No major changes in pulmonary circulation were observed, while splanchnic vascular resistance increased from 4472 +/- 1056 to 5361 +/- 1420 dyn x cm x s-5 (P less than 0.01) and estimated hepatic blood flow decreased from 1403 +/- 218 to 1218 +/- 219 ml min-1 (P less than 0.01). During endothelin-1 infusion the pulmonary vascular bed accounted for approximately 53% of the peptide's overall disposal.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1499643     DOI: 10.1111/j.1365-2362.1992.tb01463.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  8 in total

1.  Endothelin-1 response to glucose and insulin among African Americans.

Authors:  Stephanie DeLoach; Yonghong Huan; Constantine Daskalakis; Bonita Falkner
Journal:  J Am Soc Hypertens       Date:  2010-08-21

Review 2.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Agonist-dependent modulation of arterial endothelinA receptor function.

Authors:  M G Compeer; M J P M T Meens; T M Hackeng; W A Neugebauer; C Höltke; J G R De Mey
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

4.  Regional haemodynamic responses to intravenous and intraarterial endothelin-1 and big endothelin-1 in conscious rats.

Authors:  S M Gardiner; P A Kemp; T Bennett
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

5.  Clinical significance of plasma endothelin-1 in patients with chronic liver disease.

Authors:  H Matsumoto; J Uemasu; M Kitano; H Kawasaki
Journal:  Dig Dis Sci       Date:  1994-12       Impact factor: 3.199

6.  The role of endothelin-1 as a mediator of the pressure response after air embolism in blood perfused lungs.

Authors:  J Schmeck; T Koch; B Patt; A Heller; H Neuhof; K van Ackern
Journal:  Intensive Care Med       Date:  1998-06       Impact factor: 17.440

7.  Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries.

Authors:  M G Compeer; G M J Janssen; J G R De Mey
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

8.  Characterisation of preproendothelin-1 derived peptides identifies Endothelin-Like Domain Peptide as a modulator of Endothelin-1.

Authors:  Jale Yuzugulen; Julie A Douthwaite; Elizabeth G Wood; Inmaculada C Villar; Nimesh S A Patel; James Jegard; Hubert Gaertner; Irène Rossitto-Borlat; Keith Rose; Oliver Hartley; Pedro R Cutillas; Amrita Ahluwalia; Roger Corder
Journal:  Sci Rep       Date:  2017-07-10       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.